

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
NVAX | NASDAQ | USD | Real-time | |
NVV1 | TradeGate | EUR | Delayed | |
NVV1 | Frankfurt | EUR | Delayed | |
NVAX | Vienna | EUR | Real-time |
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Gregg Huber Alton | 58 | 2020 | Independent Director |
Richard Huntington Douglas | 71 | 2010 | Independent Director |
Rachel K. King | 65 | 2018 | Independent Director |
David M. Mott | 59 | 2020 | Independent Director |
Richard J. Rodgers | 57 | 2022 | Independent Director |
John Charles Jacobs | 57 | 2023 | President, CEO & Director |
Margaret G. McGlynn | 66 | 2020 | Independent Chairperson |
John W. Shiver | 66 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review